Press Room

Article / Sep 29, 2015

Hovione to expand its New Jersey facility

Manufacturing Chemist, 29 September 2015

Portuguese active pharmaceutical ingredients (APIs) and intermediates manufacturer Hovione is expanding its New Jersey facility in East Windsor, US to meet the increasing demands of its customers and to give them more options for spray drying manufacturing.

The expansion will add 30,600ft2 (2,843m2) to the 24,000ft2 (2,211m2) facility. It will include a new commercial spray dryer unit to complement the firm's existing pilot unit and this installation will be specifically designed to handle potent drug substances (APIs).

Drug substance capacity will also more than double at the site to support the needs of current and potential new customers.

Hovione said around 60 new jobs will be added to the current workforce at the plant.

 

Read the article here

Also in the Press Room

See All

The global inhalation contract development and manufacturing organization (CDMO) market is projected to grow from USD 9.13 billion in 2025 to USD 16.68 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.7% during the forecast period. This growth is driven by the increasing prevalence of respiratory diseases, advancements in inhalation drug delivery technologies, and the rising demand for outsourced manufacturing services in the pharmaceutical industry. The inhalation CDMO market has emerged as a pivotal segment in the pharmaceutical contract development and manufacturing industry. With a rising demand for inhaled therapies for conditions like asthma, COPD, and cystic fibrosis, companies are increasingly outsourcing drug development and production to specialized partners. Inhalation CDMO services cater to both large pharmaceutical corporations and small biotech firms, offering expertise in formulation, device compatibility, regulatory support, and scale-up manufacturing. This market is gaining traction due to the complexity of inhalation drug delivery, which often requires niche technical capabilities and specialized equipment. Outsourcing to an inhalation CDMO allows drug developers to reduce time-to-market while ensuring quality and compliance with global standards. (...) Top Companies Several players dominate the inhalation CDMO market through technological expertise, global reach, and service portfolio diversity: (...) Hovione – Offers particle engineering and inhalation development, with a focus on dry powder inhalers. (...) These companies are continually investing in facilities, talent, and technology to meet evolving customer needs in the inhalation CDMO market.   Read the full article on Pharmiweb.com        

Press Clipping

Inhalation CDMO Market Growth Analysis & Forecast 2025 to 2035

Jun 25, 2025